# Sickle Cell Anemia Testing and Screening Protocols

Sickle cell anemia is an inherited red blood cell disorder that affects hemoglobin, the oxygen-carrying protein within red blood cells. It causes red blood cells to become hard and sticky and assume an abnormal, sickle shape. These sickled cells die early, causing a constant shortage of red blood cells. Sickle cell anemia affects approximately 100,000 Americans.  
  
Screening Protocols and Guidelines  
Several organizations have established screening guidelines and protocols for sickle cell disease and [**Sickle Cell Anemia Testing and Screening**](https://www.coherentmarketinsights.com/industry-reports/sickle-cell-anemia-testing-and-screening-market). For example, the U.S. Department of Health and Human Services recommends that all newborns be screened for sickle cell disease. Most states have instituted universal newborn screening laws for this condition. Newborn screening for sickle cell disease involves testing a small blood sample, usually obtained from a heel prick, for abnormal hemoglobins. This early detection allows for appropriate medical management and treatment to be started right away if sickle cell disease is detected.  
  
Beyond newborn screening, the Centers for Disease Control and Prevention (CDC) recommends targeted high school and college screening for individuals of African, South or Central American, Caribbean, Middle Eastern or Mediterranean descent. High school screening allows identification of undiagnosed cases and detection of sickle cell trait which is important for reproductive counseling. College screening provides an additional opportunity given the independent living and health care access at this transitional life stage.  
  
Laboratory Testing Methods  
Several laboratory tests can confirm a diagnosis of sickle cell disease or detect sickle cell trait once screening indicates abnormal results. A complete blood count (CBC) may show low hemoglobin and red blood cell counts in addition to abnormally high numbers of reticulocytes, which are immature red blood cells. A sickledex test examines the solubility of hemoglobin under various conditions. High performance liquid chromatography (HPLC) separates and quantifies different hemoglobin variants. Genetic testing of the HBB gene identifies any mutations that cause abnormal hemoglobin production. Together, these laboratory tests can confirm the specific type of sickle cell disease or trait that is present.  
  
Carrier and Prenatal Screening  
Individuals with sickle cell trait do not have symptoms of sickle cell disease themselves but can pass the abnormal hemoglobin gene to their offspring. For this reason, targeted screening of ethnic populations allows identification of carriers to offer reproductive counseling and prenatal screening options if desired. Prenatal screening via chorionic villus sampling or amniocentesis can determine if a pregnancy is affected with sickle cell disease. This allows families to prepared for intensive medical care of an affected newborn or consider their options. The goal is empower individuals with knowledge to make the best decision for their own reproductive health and future children's wellbeing.  
  
Insurance Coverage for Screening  
While newborn screening is covered by most health insurance plans given its critical public health importance, coverage for high school, college and prenatal sickle cell screening can vary between different policies and states. Some states have passed legislation requiring private insurers to cover certain types of sickle cell screening. Advocacy organizations argue that broad screening coverage is vital to identify at-risk populations, provide reproductive health options, intervene early if disease is present, and work toward reducing sickle cell disease overall through awareness and care access. Both medical and social factors must be considered to ensure comprehensive and equitable screening programs.  
  
  
With improved screening protocols, diagnostic testing and medical management, many complications of sickle cell disease can now be prevented or treated. However, this relies on early detection through newborn, high school, college and prenatal screening programs tailored to populations at highest risk. Continued advocacy is needed to improve screening access, coverage, resources and education so that vulnerable groups can benefit from testing and have full reproductive autonomy supported by knowledge of their sickle cell status. A multi-pronged approach addressing both medical and social determinants of health has potential to significantly curb the impact of sickle cell disease over time.

**Get More Insights On**\-[**Sickle Cell Anemia Testing and Screening**](https://logcla.com/blogs/482928/Sickle-Cell-Screening-Identifying-Risks-Before-Symptoms-Appear)

**Get this Report in Japanese Language:**

[**鎌状赤血球貧血の検査とスクリーニング**](https://www.coherentmarketinsights.com/ja/%E3%82%B7%E3%82%AF%E3%83%AB%E3%82%BB%E3%83%AB%E8%B2%A7%E8%A1%80%E6%A4%9C%E6%9F%BB%E3%81%A8%E3%82%B9%E3%82%AF%E3%83%AA%E3%83%BC%E3%83%8B%E3%83%B3%E3%82%B0%E5%B8%82%E5%A0%B4)

**Get this Report in Korean Language:**

[**겸상 적혈구 빈혈 검사 및 선별**](https://www.coherentmarketinsights.com/ko/SickleCellAnemia%ED%85%8C%EC%8A%A4%ED%8A%B8%EB%B0%8F%EC%8B%AC%EC%82%AC%EC%8B%9C%EC%9E%A5-7523)

**About Author:**

**Money Singh** is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. ([https://www.linkedin.com/in/money-singh-590844163](https://www.linkedin.com/in/money-singh-590844163))